| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tian Xu, Dejuan Sun, Yi Chen, Liang Ouyan. Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors. European journal of medicinal chemistry. vol 199. 2021-02-01. PMID:32416459. |
mtor (mammalian target of rapamycin), which is a serine/threonine kinase, has been well-established as being closely correlated with the occurrence of various human diseases, such as tumors and neurodegenerative diseases. |
2021-02-01 |
2023-08-13 |
human |
| Alice Polchi, Alessandro Magini, Jarosław Mazuryk, Brunella Tancini, Jacek Gapiński, Adam Patkowski, Stefano Giovagnoli, Carla Emilian. Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization. Nanomaterials (Basel, Switzerland). vol 6. issue 5. 2020-10-01. PMID:28335215. |
recently, the use of mammalian target of rapamycin (mtor) inhibitors, in particular rapamycin (rp), has been suggested to improve the treatment of neurodegenerative diseases. |
2020-10-01 |
2023-08-13 |
Not clear |
| Amir R Afshari, Sahar Fanoudi, Arezoo Rajabian, Hamid R Sadeghnia, Hamid Mollazadeh, Azar Hossein. Potential protective roles of phytochemicals on glutamate-induced neurotoxicity: A review. Iranian journal of basic medical sciences. vol 23. issue 9. 2020-09-28. PMID:32963732. |
excessive glutamate causes an up-regulation of the multiple signaling pathways, including phosphoinositide-3 kinase/protein kinase b (pi3k/akt), akt/mammalian target of rapamycin (mtor) protein, mitogen-activated protein kinase (mapk)/extracellular signal-regulated kinase (erk)1/2, and autophagy that are involved in neurodegenerative diseases pathophysiology. |
2020-09-28 |
2023-08-13 |
Not clear |
| Paola Rusmini, Katia Cortese, Valeria Crippa, Riccardo Cristofani, Maria Elena Cicardi, Veronica Ferrari, Giulia Vezzoli, Barbara Tedesco, Marco Meroni, Elio Messi, Margherita Piccolella, Mariarita Galbiati, Massimiliano Garrè, Elena Morelli, Thomas Vaccari, Angelo Polett. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. vol 15. issue 4. 2020-05-11. PMID:30335591. |
abbreviations: als: amyotrophic lateral sclerosis; ar: androgen receptor; atg: autophagy related; av: autophagic vacuole; bag3: bcl2-associated athanogene 3; becn1: beclin 1, autophagy related; casa: chaperone-assisted selective autophagy; ctsb: cathepsin b; dapi: 4',6-diamidino-2-phenylindole; dmem: dulbecco's modified eagle's medium; egfp: enhanced green fluorescent protein; fals, familial amyotrophic lateral sclerosis; fra: filter retardation assay; gapdh: glyceraldehyde-3-phosphate dehydrogenase; gla: galactosidase, alpha; hd: huntington disease; hipscs: human induced pluripotent stem cells; hspa8: heat shock protein a8; hspb8: heat shock protein b8; if: immunofluorescence analysis; lamp1: lysosomal-associated membrane protein 1; lamp2a: lysosomal-associated membrane protein 2a; lgals3: lectin, galactose binding, soluble 3; llome: l-leucyl-l-leucine methyl ester; lmp: lysosomal membrane permeabilization; lys: lysosomes; map1lc3b: microtubule-associated protein 1 light chain 3 beta; mcoln1: mucolipin 1; mrna: messenger rna; mtor: mechanistic target of rapamycin kinase; nds: neurodegenerative diseases; nsc34: neuroblastoma x spinal cord 34; pbs: phosphate-buffered saline; pd: parkinson disease; polyq: polyglutamine; ppargc1a: peroxisome proliferative activated receptor, gamma, coactivator 1 alpha; ppp3cb: protein phosphatase 3, catalytic subunit, beta isoform; rt-qpcr: real-time quantitative polymerase chain reaction; sbma: spinal and bulbar muscular atrophy; scas: spinocerebellar ataxias; sirna: small interfering rna; slc2a8: solute carrier family 2, (facilitated glucose transporter), member 8; smnpcs: small molecules neural progenitors cells; sod1: superoxide dismutase 1; sqstm1/p62: sequestosome 1; sted: stimulated emission depletion; stub1: stip1 homology and u-box containing protein 1; tardbp/tdp-43: tar dna binding protein; tfeb: transcription factor eb; tpp1: tripeptidyl peptidase i; treh: trehalase (brush-border membrane glycoprotein); wb: western blotting; zkscan3: zinc finger with krab and scan domains 3. |
2020-05-11 |
2023-08-13 |
human |
| Xiangyong Wei, Lingfei Luo, Jinzi Che. Roles of mTOR Signaling in Tissue Regeneration. Cells. vol 8. issue 9. 2020-05-11. PMID:31547370. |
the dysregulation of mtor is involved in human diseases including cancer, cardiovascular diseases, neurodegenerative diseases, and epilepsy. |
2020-05-11 |
2023-08-13 |
human |
| Haruhiro Higashida, Shin-Ya Kamimura, Takeshi Inoue, Osamu Hori, Mohammad Saharul Islam, Olga Lopatina, Chiharu Tsuj. Cyclic ADP-ribose as an endogenous inhibitor of the mTOR pathway downstream of dopamine receptors in the mouse striatum. Journal of neural transmission (Vienna, Austria : 1996). vol 125. issue 1. 2019-09-30. PMID:28025713. |
these data suggest that cadpr is an endogenous inhibitor of the mtor signaling pathway downstream of da receptors in the mouse striatum and that cadpr plays a certain role in the brain in psychiatric and neurodegenerative diseases. |
2019-09-30 |
2023-08-13 |
mouse |
| Mohammed S Abdel-Maksoud, Mohammed I El-Gamal, Dalia Reyane Benhalilou, Sandy Ashraf, Shatha Abdulghaffar Mohammed, Chang-Hyun O. Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors. Medicinal research reviews. vol 39. issue 2. 2019-06-17. PMID:30251347. |
overstimulation of mtor by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. |
2019-06-17 |
2023-08-13 |
Not clear |
| Mohammed S Abdel-Maksoud, Mohammed I El-Gamal, Dalia Reyane Benhalilou, Sandy Ashraf, Shatha Abdulghaffar Mohammed, Chang-Hyun O. Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors. Medicinal research reviews. vol 39. issue 2. 2019-06-17. PMID:30251347. |
in this study, we reviewed the recent advances regarding the mechanism that involves mtor in cancer, aging, and neurodegenerative diseases. |
2019-06-17 |
2023-08-13 |
Not clear |
| Arash Soltani, Amirhossein Bahreyni, Nadia Boroumand, Mostafa Karimi Roshan, Majid Khazaei, Mikhail Ryzhikov, Saman Soleimanpour, Amir Avan, Seyed Mahdi Hassania. Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. Journal of cellular physiology. vol 233. issue 6. 2019-04-15. PMID:29165795. |
in this review, we summarize recent findings on the regulatory effects of mtor signaling on inflammation and the therapeutic potency of mtor pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. |
2019-04-15 |
2023-08-13 |
Not clear |
| Samira Shirooie, Seyed Fazel Nabavi, Ahmad R Dehpour, Tarun Belwal, Solomon Habtemariam, Sandro Argüelles, Antoni Sureda, Maria Daglia, Michał Tomczyk, Eduardo Sobarzo-Sanchez, Suowen Xu, Seyed Mohammad Nabav. Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration? Pharmacological research. vol 135. 2019-04-10. PMID:29990625. |
the role of mtor in neurodegenerative diseases and targeted therapies by pufas are discussed. |
2019-04-10 |
2023-08-13 |
Not clear |
| Fabio Di Domenico, Antonella Tramutola, Cesira Foppoli, Elizabeth Head, Marzia Perluigi, D Allan Butterfiel. mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Free radical biology & medicine. vol 114. 2019-03-13. PMID:28807816. |
the mtor pathway represents a key growth and survival pathway involved in several diseases such as cancer, obesity, cardiovascular disease and neurodegenerative diseases. |
2019-03-13 |
2023-08-13 |
human |
| Yassine El Hiani, Emmanuel Eroume-A Egom, Xian-Ping Don. mTOR signalling: jack-of-all-trades Biochemistry and cell biology = Biochimie et biologie cellulaire. vol 97. issue 1. 2019-03-06. PMID:29768134. |
mtor deregulation is implicated in a broad range of pathological conditions, including diabetes, cancer, neurodegenerative diseases, myopathies, inflammatory, infectious, and autoimmune conditions. |
2019-03-06 |
2023-08-13 |
human |
| Ying-Chun Liu, Xiao-Xiao Gao, Ling Chen, Xiao-Qing Yo. Rapamycin suppresses Aβ Neuroscience. vol 355. 2018-03-28. PMID:28504198. |
rapamycin suppresses aβ rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), exhibits a high neuroprotective action against neurodegenerative diseases in mouse models. |
2018-03-28 |
2023-08-13 |
mouse |
| Kenneth Maies. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. British journal of clinical pharmacology. vol 82. issue 5. 2017-12-29. PMID:26469771. |
the mechanistic target of rapamycin (mtor), also known as the mammalian target of rapamycin, is a 289 kda serine/threonine protein kinase that offers exciting possibilities for novel treatment strategies for a host of neurodegenerative diseases that include alzheimer's disease, parkinson's disease, huntington's disease, epilepsy, stroke and trauma. |
2017-12-29 |
2023-08-13 |
Not clear |
| Xinde Zheng, Leah Boyer, Mingji Jin, Yongsung Kim, Weiwei Fan, Cedric Bardy, Travis Berggren, Ronald M Evans, Fred H Gage, Tony Hunte. Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. eLife. vol 5. 2017-10-31. PMID:27008180. |
mtor inhibition is beneficial in neurodegenerative disease models and its effects are often attributable to the modulation of autophagy and anti-apoptosis. |
2017-10-31 |
2023-08-13 |
Not clear |
| Anna Jeong, Michael Won. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology. Current neurology and neuroscience reports. vol 16. issue 12. 2017-08-07. PMID:27815691. |
the mammalian/mechanistic target of rapamycin (mtor) pathway is a key signaling pathway that has been implicated in genetic epilepsy syndromes, neurodegenerative diseases, and conditions associated with autism spectrum disorder and cognitive impairment. |
2017-08-07 |
2023-08-13 |
Not clear |
| Wenzhen Shen, Keliang Lu, Jiawan Wang, Anshi Wu, Yun Yu. Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through β-amyloid accumulation and tau phosphorylation. Molecular medicine reports. vol 14. issue 4. 2017-04-04. PMID:27599409. |
the mammalian target of rapamycin (mtor) signaling pathway has been reported to be crucial in the pathophysiology of neurodegenerative diseases. |
2017-04-04 |
2023-08-13 |
mouse |
| Bin Fan, Fu-Qaing Li, Jing-Yao Song, Xu Chen, Guang-Yu L. Inhibition of mTOR signaling protects photoreceptor cells against serum deprivation by reducing oxidative stress and inducing G2/M cell cycle arrest. Molecular medicine reports. vol 13. issue 5. 2017-02-16. PMID:27035647. |
these observations may provide evidence for the treatment of retinal degenerative disease, since inducing neurons into a lower and more stable bioenergetic state by blocking mtor signaling may slow the progression of neurodegenerative diseases. |
2017-02-16 |
2023-08-13 |
Not clear |
| Antonella Tramutola, Chiara Lanzillotta, Andrea Arena, Eugenio Barone, Marzia Perluigi, Fabio Di Domenic. Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome. Neuro-degenerative diseases. vol 16. issue 1-2. 2016-09-20. PMID:26606243. |
neurodegenerative diseases are characterized by increased levels of oxidative stress and an altered mammalian target of rapamycin (mtor)/autophagy axis; however, the mutual relationship between these two events is controversial. |
2016-09-20 |
2023-08-13 |
mouse |
| Caio Henrique Mazucanti, João Victor Cabral-Costa, Andrea Rodrigues Vasconcelos, Diana Zukas Andreotti, Cristoforo Scavone, Elisa Mitiko Kawamot. Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration. Current topics in medicinal chemistry. vol 15. issue 21. 2016-05-31. PMID:26059361. |
in this review we focus on the current advances involving the mtor, sirt and iis longevity pathways during the course of healthy aging processes and neurodegenerative diseases, bringing new insights in the form of a better understanding of the signaling mechanisms underpinning neurodegeneration and how these differ from physiological normal aging processes. |
2016-05-31 |
2023-08-13 |
Not clear |